DEA proudly announces the release of its new agency seal, symbolizing the agency’s unwavering commitment to saving lives and protecting the safety and well-being of communities across the nation. This updated seal represents more than just a refreshed design — it is a reaffirmation of our values and an acknowledgment...

WASHINGTON – The hearing scheduled to begin on Tuesday, January 21, 2025, regarding the proposed rescheduling of marijuana has been postponed pending resolution of an appeal filed by a party in the proceedings. The order is available on DEA.gov .

The U.S. Drug Enforcement Administration has released the 2024 edition of Drugs of Abuse, A DEA Resource Guide , which is designed to be a reliable resource on the most commonly used and misused drugs in the United States. Released on a periodic basis, Drugs of Abuse provides important science-based...

DEA is committed to making sure patients can get the care they need in the event a doctor or medical facility is unable to provide treatment due to enforcement action against the medical provider. On October 5, 2023, DEA arrested a nurse practitioner in Buffalo, New York, on charges of...

Fentanyl is the greatest threat facing Americans today. It is a threat to our public health, our public safety, and our national security, and it is the cause of the most devastating drug crisis in United States’ history. The U.S. Drug Enforcement Administration (DEA) is committed to using every tool...

Washington, D.C. – The U.S. Drug Enforcement Administration (DEA) is focused on saving American lives by defeating the cartels responsible for bringing fentanyl into our country. The threat of fentanyl is deadlier and more pervasive than ever before. When I joined DEA in 2021, DEA laboratory testing indicated 4 out...

On July 26, 2023, DEA temporarily scheduled five synthetic benzodiazepine substances – etizolam, flualprazolam, clonazolam, flubromazolam, and diclazepam – in schedule I of the Controlled Substances Act (CSA). Individuals who handle these substances will now be subject to regulatory controls, as well as to administrative, civil, and criminal sanctions applicable...

The U.S. Drug Enforcement Administration and the U.S. Department of Homeland Security are updating the American public on the ongoing threat of illicit xylazine. In April 2023, the White House Office of National Drug Control Policy (ONDCP) designated fentanyl adulterated or associated with xylazine as an emerging threat to the...

Patients now have the ability to request their electronic prescription be transferred to another pharmacy without having to go back to their practitioner to initiate the request. This revised regulation went into effect on Monday, August 28, 2023. At a patient’s request, a DEA-registered retail pharmacy can now transfer an...

Following a successful Family Summit on fentanyl in September of 2022, the El Paso Division outreach team has been working with Bernalillo County leadership to create more prevention education opportunities for employers. So, in July as part of Operation Engage, the DEA sponsored a CADCA training which was hosted at...